#USA #San Diego #Field Medical #Heart Rhythm #PFA Technology

Significant Breakthrough in Cardiac Ablation Technology

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, announced a major milestone at the Heart Rhythm Society’s 2025 annual meeting, showcasing initial human results from their innovative FieldForce™ Ablation System. The conference, held in San Diego, California, from April 24-27, brought together over 9,000 participants and 2,000 experts in the field of electrophysiology, highlighting the importance of advancements in cardiac treatments.

This year’s Heart Rhythm conference was marked by Field Medical's series of eight impactful presentations, which included groundbreaking research, live case demonstrations, and the latest clinical trials. Among the highlights was the much-anticipated VCAS study, which revealed acute data on the first human applications of focal PFA aimed at treating scar-related ventricular tachycardia (VT), a challenging arrhythmia often characterized by dense fibrotic substrates and high recurrence rates.

Dr. Steven Mickelsen, CEO and Founder of Field Medical, emphasized the significance of the FieldForce™ Ablation System in redefining the treatment landscape for patients suffering from this complex condition. “For decades, scar-related VT has presented a formidable challenge even for the most skilled electrophysiologists,” he stated. “With FieldForce, we are not merely iterating old technologies; we are redefining what’s possible. This new focal PFA system has the potential to bring our advanced ablation techniques to areas where electrophysiological needs are most urgent.”

The FieldForce™ Ablation System catheter is meticulously designed to reach the epicardium from the endocardium, enabling effective focal pulsed field ablation for transmural lesions. This innovative approach targets the intricate and difficult substrates found in scar-related VT, aiming not just for ablation but for durable success in preventing arrhythmia recurrence.

During the conference, Field Medical presented various cases demonstrating real-world applications of their technology. The sessions included clinical trial results, poster presentations on lesion effectiveness, and discussions on the modulation of scar tissue following treatment. Topics explored included:

• - Live Case Demonstrations: Featuring Drs. Vivek Reddy and Petr Neužil, focusing on applications of the PFA system in clinical settings.
• - Poster Presentations: Discussing the treatment of refractory VT with experimental PFA systems, as well as results on transmural lesion creation.
• - Satellite Symposium: An engaging event at the San Diego Wine & Culinary Center, where leading experts discussed the future of ablative therapies and the role of PFA in ventricular applications.

Field Medical's commitment to advancing cardiac treatment innovation was evident throughout the event, which featured prominent figures in the medical community, including members from leading institutions such as Stanford Biodesign and the New Arrhythmia Technologies group. Their participation reflects a unified effort to enhance treatment modalities and patient outcomes in the realm of cardiac health.

As the conference wrapped up, excitement was palpable regarding the potential applications of the FieldForce™ technology in clinical practice. As the industry continues to evolve, innovations such as the FieldForce™ Ablation System are crucial in driving improved patient outcomes for those suffering from complex arrhythmias.

Founded in 2022, Field Medical is at the forefront of developing next-generation PFA technologies aimed at addressing the intricate needs of modern cardiac ablation. Their groundbreaking work has already garnered recognition, such as the FDA's Breakthrough Device Designation and inclusion in the TAP Pilot Program, underscoring their commitment to innovation and excellence in healthcare.

For more information about Field Medical and their pioneering technologies, please visit their website at www.fieldmedicalinc.com and follow them on LinkedIn and X.